OCX: OncoCyte Corp. Price-to-Revenue Coefficient

The commercialization of OncoCyte Corporation (OCX) molecular tests is in its early stages, which creates significant pressure on costs. Comparing the price-to-sales ratio on GURU.Markets, we see that the metric is fixed at 24.00. OncoCyte Corporation (OCX) focuses on liquid biopsy for monitoring recurrences and transplants. The business possesses exceptional macro-resilience, as cancer diagnostics are independent of economic cycles and seasonality.

OncoCyte Corp. (OCX): Price-to-Revenue Ratio from 07/04/2022 to 06/18/2025

Analytical breakdowns for OncoCyte Corp. (OCX)

- price and consensus price forecast:

Market Chart oncocyte.com|OCX - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization OncoCyte Corp.|OCX - Total Company Value

- company book value details:

Net Assets per Share OncoCyte|OCX - Company Book Value|Market-to-Book Ratio oncocyte.com|OCX - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

OCX - Net Income|Future Net Profit OncoCyte Corporation|OCX - P/E Multiple|Projected Price to Earnings Ratio OncoCyte Corp|OCX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation OncoCyte Corp.|OCX - Operating profit EBITDA|Net earnings per share for the last 12 months OncoCyte|OCX - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months oncocyte.com|OCX - Earnings per share growth in current year|Expected earnings per share trend next year OncoCyte Corporation

- total revenue and sales volume data:

OCX - Company Revenue|Company Expected Revenue oncocyte.com|OCX - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio OncoCyte Corp.

Fundamental company analysis:OCX - oncocyte.com

Manufactured products of OncoCyte Corporation

Stable demand for early cancer diagnostics makes the OncoCyte Corporation (OCX) business resilient to macroeconomic shocks. The relationship between market capitalization and sales volume, represented by the price-to-sales ratio, measures the premium the market is willing to pay for future revenue growth, allowing investors to identify overinflated expectations or asset undervaluation before official financial reports are published.

Competing companies